Over the last two decades, the medical device industry has made major advances in providing patient benefits. Traditional surgical approaches have been replaced or augmented by minimally invasive procedures and implantable medical devices have improved in their durability and wear. These improvements have been driven largely by advances in technology - the ability to manufacture miniaturized instrumentation and cameras, improved imaging abilities, and new materials and processes.

The emergence of drug-eluting devices was certainly the next logical advance for interventional cardiology, and the development of innovative drug-delivery systems and combination products will continue to advance this field.

Micell's supercritical fluid-based surface modification technology has the potential to address certain limitations of traditional solvent-based methods and to provide new processing methods within the combination products marketplace.